Lupus Nephritis Clinical Trial
Official title:
A Pilot Study of Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis
This a single-centre, one-arm, open-label pilot study. Eligible patients with mild proteinuric flares of lupus nephritis Class III/IV±V are received sirolimus without changing previous immunosuppressive medication during 12-week follow-up. Primary Objective: - To investigate the efficacy of sirolimus for mild proteinuric flares in patients with Class III/IV±V lupus nephritis Secondary Objective: - To assess the safety and tolerability of sirolimus treatment for mild proteinuric flares in patients with Class III/IV±V lupus nephritis
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | October 30, 2023 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Biopsy-proven Class III or IV±V lupus nephritis (ISN/RPS 2003 lupus nephritis classification) with biopsy performed within 48 weeks before inclusion. - Males or females aged 18 to 60 years old at the time of screening. - The mild proteinuric flare of lupus nephritis is defined as meeting all of the following criteria : 1. Persistently increased proteinuria after complete remission, and 24-hr proteinuria=1.0g/day or doubling of proteinuria after partial remission, and 24-hr proteinuria=2.0g/day 2. No hypoalbuminemia: serum albumin =35g/L 3. Stable renal function: serum creatinine<25% increase above the level at the time of renal disease remission - Eligible to sign informed-consent independently Exclusion Criteria: - Renal disease unrelated to SLE (e.g. diabetes mellitus, other glomerular or tubulointerstitial diseases, renovascular disease), or transplanted kidney - Estimate glomerular filtration rate (eGFR by CKD-EPI)<45mL/min per 1.73m^2 at the time of screening - Renal biopsy showing cellular of fibrocellular crescent in more than 25% of glomeruli - Central nervous system (CNS) or other severe organ manifestations of lupus that necessitate aggressive immunosuppressive therapy on its own. - Co-morbidities that require corticosteroid therapy (e.g. asthma, inflammatory bowel disease) - Any increased dose of corticosteroids or other immunosuppressive medication including cyclophosphamide, mycophenolate, leflunomide, calcineurin inhibitors, azathioprine, methotrexate, or use of biological agents regardless of duration, with the past six months - Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection history: seropositivity of HBV surface antigen (HBsAg) or HCV antibodies (HCV-Ab) - Women who are pregnant or breastfeeding - Women with childbearing potential or their male partners, who refuse to use an effective birth control method |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Peking Union Medical College Hospital | North China Pharmaceutical Group Corporation |
Eriksson P, Wallin P, Sjöwall C. Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus. Front Pharmacol. 2019 Feb 6;10:82. doi: 10.3389/fphar.2019.00082. eCollection 2019. — View Citation
Esatoglu SN, Seyahi E. Is sirolimus a treatment option for patients with systemic lupus erythematosus? Clin Exp Rheumatol. 2019 Nov-Dec;37 Suppl 122(6):13. Epub 2019 Jul 12. — View Citation
Lai ZW, Kelly R, Winans T, Marchena I, Shadakshari A, Yu J, Dawood M, Garcia R, Tily H, Francis L, Faraone SV, Phillips PE, Perl A. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet. 2018 Mar 24;391(10126):1186-1196. doi: 10.1016/S0140-6736(18)30485-9. Epub 2018 Mar 15. — View Citation
Ma MKM, Yung S, Chan TM. mTOR Inhibition and Kidney Diseases. Transplantation. 2018 Feb;102(2S Suppl 1):S32-S40. doi: 10.1097/TP.0000000000001729. Review. — View Citation
Yap DYH, Tang C, Chan GCW, Kwan LPY, Ma MKM, Mok MMY, Chan TM. Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis. J Rheumatol. 2018 Dec;45(12):1663-1670. doi: 10.3899/jrheum.180507. Epub 2018 Oct 1. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The number of patients achieving sustained Renal Response(RR) | Sustained RR is defined as satisfying all of the following criteria:
1)Proteinuria is improved by =50% compared with baseline 2)24-hr urine protein < 1g 3)Serum creatinine is not higher than 15% above baseline level 4)No occurrence of non-renal disease flare after achieving response to treatment. |
at the end of 12 weeks (3 months) from baseline | |
Secondary | Complete renal remission | 24-hr urine protein<0.3g/day or urine Protein-Creatinine ratio (uPCR)<300mg/g
Serum creatinine not higher than 15% above baseline level |
at the end of 12 weeks (3 months) from baseline | |
Secondary | Partial renal remission | 24-hr urine protein<3.5g/day or uPCR<3500mg/g
Serum creatinine not higher than 15% above baseline level |
at the end of 12 weeks (3 months) from baseline | |
Secondary | Rate of non-renal flare | Central nervous system or other severe organ manifestations of SLE that necessitate aggressive immunosuppressive therapy on its own | during the 3-month follow up | |
Secondary | Safety and tolerability of study medications | The following parameters will be monitored:
Increase of serum creatinine level>15% from baseline and whether it is reversible or irreversible Episodes with sirolimus level above the target range New-onset hypertension or worsening hypertensive control that required increase of antihypertensive medication Infectious requiring hospitalization and the causative agents Hospitalization episodes- cause, duration (days) Hypokalemia: serum potassium <3.5mmol/L Metabolic acidosis with HCO3 <17mmol/L New-onset hypercholesterolemia present at 3 months or beyond from baseline and/or addition of lipid-lowering drug(s). Premature discontinuation from the study due to treating intolerance Premature discontinuation from the study due to rapid disease progression or other reasons Failure to adhere to the protocol defined corticosteroid reduction regimen Other adverse clinical events or events considered clinically significant |
during the 3-month follow up | |
Secondary | Increase of serum creatinine level>15% from baseline | Increase of serum creatinine level (µmol/L)>15% from baseline and whether it is reversible or irreversible. | during the 3-month follow up | |
Secondary | Episodes with sirolimus level above the target range | Episodes with sirolimus level above the target range(serum sirolimus trough level>8ng/mL) will be recorded. | during the 3-month follow up | |
Secondary | New-onset hypertension or worsening hypertensive control that required increase of antihypertensive medication | Hypertension be diagnosed when a person's systolic blood pressure (SBP) in the office or clinic is =140 mm Hg and/or their diastolic blood pressure (DBP) is =90 mm Hg following repeated examination.
New-onset hypertension or worsening hypertensive control that required increase of antihypertensive medication will be recorded. |
during the 3-month follow up | |
Secondary | Infection requiring hospitalization | Infection requiring hospitalization will be recorded including the site of infection, the causative agent and duration (days). | during the 3-month follow up | |
Secondary | Hypokalemia | Serum potassium <3.5mmol/L | during the 3-month follow up | |
Secondary | Hypercholesterolemia | New-onset hypercholesterolemia present during follow-up or beyond from baseline and/or addition of lipid-lowering drug(s) | during the 3-month follow up | |
Secondary | Premature discontinuation from the study | The time of of discontinuation from study will be recorded, and the discontinuation is due to:
treating intolerance rapid disease progression other reasons |
during the 3-month follow up | |
Secondary | Failure to adhere to the protocol | Failure to adhere to the protocol including:
do not titer the dose of sirolimus following study protocol increase the dose of other immunosuppressives personally without the permission of physician |
during the 3-month follow up | |
Secondary | Changes in Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) | Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) assesses disease activity by scoring 24 weighted disease activity descriptors of SLE as "present" or "absent" in preceding 10 days. A patient's total score is the sum of all marked SLE-related descriptors; a total score ranges between 0 and 105, with a higher score representing a more significant degree of disease activity.
Assessment scales of SELENA-SLEDAI is available online. |
from baseline to end of 12 weeks | |
Secondary | Changes in Physician Global Assessement (PGA) | The Physician Global Assessment (PGA) is a visual analog scale (VAS) using 3 benchmarks for assessing disease activity over the last 2 weeks. Mild flare will score 1.0 point, moderate flares will score a 2.0-2.5 point and severe flares will score a 3 on the 0-3 analog scale. PGA is available online. | from baseline to end of 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02936375 -
The Iguratimod Effect on Lupus Nephritis (IGeLU)
|
Phase 2 | |
Completed |
NCT03597464 -
Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
|
Phase 3 | |
Recruiting |
NCT01226147 -
Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis
|
Phase 2 | |
Completed |
NCT01206569 -
Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis
|
Phase 4 | |
Active, not recruiting |
NCT00569101 -
A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis
|
Phase 2 | |
Terminated |
NCT00368264 -
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
|
Phase 2/Phase 3 | |
Completed |
NCT00371319 -
Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis
|
Phase 4 | |
Completed |
NCT00298506 -
Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)
|
N/A | |
Completed |
NCT00094380 -
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
|
Phase 1/Phase 2 | |
Terminated |
NCT04376827 -
A Study of Guselkumab in Participants With Active Lupus Nephritis
|
Phase 2 | |
Completed |
NCT03610516 -
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.
|
Phase 2 | |
Recruiting |
NCT03526042 -
Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis
|
N/A | |
Withdrawn |
NCT03859570 -
Pentoxifylline in Lupus Nephritis
|
Phase 4 | |
Completed |
NCT03664908 -
Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)?
|
N/A | |
Completed |
NCT01085097 -
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
|
Phase 2 | |
Active, not recruiting |
NCT05704088 -
SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients
|
Phase 4 | |
Not yet recruiting |
NCT06429800 -
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis
|
Phase 1 | |
Recruiting |
NCT02226341 -
ACTHar in the Treatment of Lupus Nephritis
|
Phase 4 | |
Recruiting |
NCT02453997 -
Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis
|
N/A | |
Completed |
NCT01470183 -
Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients
|
N/A |